-
Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer
-
Kyungsuk Jung, Jong Chul Park, Hyunseok Kang, Johann Christoph Brandes
-
Epidemiol Health. 2018;40:e2018040. Published online August 11, 2018
-
DOI: https://doi.org/10.4178/epih.e2018040
-
-
14,302
View
-
207
Download
-
7
Web of Science
-
6
Crossref
-
Abstract
Summary
PDFSupplementary Material
-
Abstract
OBJECTIVES We investigated whether androgen deprivation therapy (ADT) in prostate cancer patients was associated with a decreased risk for second primary lung cancer in US veterans.
METHODS Prostate cancer diagnoses in the US Veterans Affairs Cancer Registry between 1999 and 2008 were identified. Use of hormonal therapy and diagnoses of second primary lung cancer were determined from the registry. Synchronous prostate and lung cancers, defined as 2 diagnoses made within 1 year, were excluded from the analysis. Cancer-free survival was estimated using the Kaplan-Meier method and hazard ratios were estimated using Cox proportional hazard models.
RESULTS Among the 63,141 identified patients with prostate cancer, 18,707 subjects were eligible for the study. Hormonal therapy was used in 38% of patients and the median follow-up period was 28 months. ADT use was associated with longer lung cancer-free survival in prostate cancer patients (log-rank p=0.01). After adjusting for age, race, smoking and prostate cancer stage, ADT use was associated with decreased lung cancer risk by 15, 21, and 24% after 1, 2, and 3 years, respectively.
CONCLUSIONS ADT in prostate cancer patients may be associated with decreased second primary lung cancer risk among US veterans.
-
Summary
Korean summary
비소세포성 폐암이 호르몬 수용체에 의해 영향을 받을 수 있다는 기존의 연구 결과를 바탕으로, 이 연구는 미국 재향 군인 병원 암등록 자료를 분석하여 전립선암 환자 중, 안드로겐 박탈 요법으로 치료를 받은 경우와 그렇지 않은 경우의 비소세포성 폐암 발생율을 비교분석하였다. 분석 결과, 전립선암을 진단받은 미국 재향군인들 중 안드로겐 박탈 요법으로 치료를 받은 환자들이 그렇지 않은 환자들에 비해 비소세포성 폐암 발생율이 통계적으로 유의미하게 감소하는 것이 관찰되었다.
-
Citations
Citations to this article as recorded by
- Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients
Xinyu Wang, Meiyuan Zeng, Xueming Ju, Anqi Lin, Chaozheng Zhou, Junyi Shen, Zaoqu Liu, Bufu Tang, Quan Cheng, Youyu Wang, Jian Zhang, Peng Luo British Journal of Surgery.2024;[Epub] CrossRef - New Perspectives on Sex Steroid Hormones Signaling in Cancer-Associated Fibroblasts of Non-Small Cell Lung Cancer
Chihiro Inoue, Yasuhiro Miki, Takashi Suzuki Cancers.2023; 15(14): 3620. CrossRef - Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
Vianey Rodriguez-Lara, Giovanny Soca-Chafre, Maria Rosa Avila-Costa, Juan Jose Juarez-Vignon Whaley, Jeronimo Rafael Rodriguez-Cid, José Luis Ordoñez-Librado, Emma Rodriguez-Maldonado, Nallely A. Heredia-Jara Frontiers in Oncology.2023;[Epub] CrossRef - Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never‐smoking women
Yingya Zhao, Yu‐Tang Gao, Xianglan Zhang, Alan L. Rockwood, Mark M. Kushnir, Qiuyin Cai, Jie Wu, Jiajun Shi, Qing Lan, Nathaniel Rothman, Yu Shyr, Xiao‐Ou Shu, Wei Zheng, Gong Yang International Journal of Cancer.2022; 151(5): 699. CrossRef - Racial and ethnic differences in risk of second primary cancers among prostate cancer survivors
Diana R. Withrow, Sara J. Schonfeld, Rochelle E. Curtis, Lindsay M. Morton, Michael B. Cook, Eboneé N. Butler, Amy Berrington de González Cancer Causes & Control.2020; 31(11): 1011. CrossRef - Sex steroid metabolism and actions in non-small cell lung carcinoma
Teeranut Asavasupreechar, Monica S.M. Chan, Ryoko Saito, Yasuhiro Miki, Viroj Boonyaratanakornkit, Hironobu Sasano The Journal of Steroid Biochemistry and Molecular Biology.2019; 193: 105440. CrossRef
|